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There is strong evidence that vasodilatory nitric oxide (NO) donors have anabolic effects on bone in humans. Parathyroid hormone (PTH), the
only osteoanabolic drug currently approved, is also a vasodilator. We investigated whether the NO synthase inhibitor L-NAME might alter the
effect of PTH on bone by blocking its vasodilatory effect. BALB/c mice received 28 daily injections of PTH[1–34] (80 μg/kg/day) or
L-NAME (30mg/kg/day), alone or in combination. Hindlimb blood perfusion was measured by laser Doppler imaging. Bone architecture,
turnover and mechanical properties in the femur were analysed respectively by micro-CT, histomorphometry and three-point bending.
PTH increased hindlimb blood flow by >30% within 10min of injection (P< 0.001). Co-treatment with L-NAME blocked the action
of PTH on blood flow, whereas L-NAME alone had no effect. PTH treatment increased femoral cortical bone volume and formation rate
by 20% and 110%, respectively (P< 0.001). PTH had no effect on trabecular bone volume in the femoral metaphysis although trabecular
thickness and number were increased and decreased by 25%, respectively. Co-treatment with L-NAME restricted the PTH-stimulated
increase in cortical bone formation but had no clear-cut effects in trabecular bone. Co-treatment with L-NAME did not affect the mechanical
strength in femurs induced by iPTH. These results suggest that NO-mediated vasorelaxation plays partly a role in the anabolic action of PTH
on cortical bone. © 2016 The Authors. Cell Biochemistry and Function published by John Wiley & Sons, Ltd.
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INTRODUCTION
The cardiovascular action of parathyroid hormone (PTH)
was first observed in 1925, soon after its discovery as a
hypercalcaemic agent 1. Decades later, PTH was shown to
decrease arterial blood pressure and increase cardiac output,
with marked increases in coeliac, coronary and renal blood
flows and corresponding decreases in vascular resistance 2,3.
PTH also has an opposing hypertensive action, secondary to
its potent hypercalcemic effect 4.
Since the discovery of the powerful osteoanabolic effect of
intermittently administrated PTH (iPTH)5, research has focused
mainly on its skeletal effects; iPTH remains the most potent
bone anabolic drug available at present 6. There is good
evidence that a key mechanism underlying the osteogenic
action of PTH is the suppression of sclerostin production 7, an
inhibitor of Wnt signalling that is predominantly produced by
osteocytes and hypertrophic chondrocytes 8. Further evidence
that the effect of PTH on bone is mediated by bone cells is
provided from genetic studies where selective activation or
disruption of PTH receptor type 1 (PTHR1) signalling in
osteocytes modified the anabolic and catabolic responses
induced by PTH in mice 9,10. One key aspect underpinning
the complex in vivo role of PTH, which merits consideration
when exploring its mode of action, is its pivotal dependence
on mode of administration: although intermittent injections of
PTH increase bone mass, continuous infusion stimulates osteo-
clastic resorption and decreases bone mass11,12. Surprisingly,
the direct effect of PTH on primary rodent osteoblasts in vitro
is to strongly inhibit osteogenic differentiation and bone
formation 13,14. This observation suggests that an additional
indirect action of the hormone could contribute to the
osteoanabolic effect of PTH on bone in vivo.
In recent years, considerable evidence has emerged in
support of the critical role of the vascular supply in the
control of bone formation and turnover 15–19. The possibility
that some osteogenic effects of iPTH rely on its vascular
function has yet, however, to be fully explored. PTHR1 is
expressed by many cell types, including endothelial and
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vascular smooth muscle cells 20,21. PTH has recently been
shown to increase blood perfusion of bone marrow in the
mouse tibia in a manner that correlated strongly with bone
remodelling parameters 22. The same study also showed that
iPTH moderately increased intraosseous angiogenesis and
blood vessel remodelling within the bone marrow. Based
on these results and those of a previous study in rats 23,
the authors concluded that the combination of vascular
remodelling and vasotonic action underpins the increase in
bone perfusion induced by iPTH. Both the vascular remod-
elling and the osteoanabolic effects of iPTH have been
shown to depend on the potent angiogenic factor, vascular
endothelial growth factor (VEGF), whose production is
directly stimulated by PTH in bone 23, and bone and endo-
thelial cells 24,25. A recent report showed that VEGF signal-
ling was involved in mediating PTH-induced vasorelaxation
in isolated femoral principal nutrient arteries (PNAs),
suggesting that it may also partly mediate the osteoanabolic
effect of PTH in vivo 26. Interestingly, this study also
revealed a strong dependency of PTH vasodilatory effect
in PNAs on nitric oxide synthase (NOS) activity 26.
Although these studies suggest that the osteoanabolic action
of iPTHmay depend on its vascular effects, it is still unknown
whether the acute vasodilatory effect of iPTH could be
involved in augmenting bone blood flow during the course
of treatment. Similarly, whilst the osteoanabolic effects of
several NO donor drugs are well documented 27, it is not
known whether the transient vasorelaxation induced daily by
these drugs constitutes an essential component of their mech-
anism of action. The physiological need for increasing blood
supply in response to the metabolic demands of increased
bone formation and turnover is well-documented 16. In the
present study we investigated whether the acute vasodilatory
effect of PTH contributes to limb blood flow, bone perfusion
and, ultimately, to its osteoanabolic action.
MATERIAL AND METHODS
Drugs and reagents
Human PTH (1–34), bovine serum albumin (BSA), Nω-nitro-
L-arginine methyl ester hydrochloride (L-NAME), procion
red MX-5B, calcein and xylenol orange were purchased from
Sigma (UK). Phosphate buffered saline solution (PBS) was
purchased from VWR (UK). All drugs were used at a dose
required to produce the desired pharmacological effects in
mice, according to previous protocols 28,29.
Experimental design
Male BALB/c mice, aged 10–12weeks, were purchased from
Charles River Laboratories, Ins (UK) and maintained under a
controlled temperature (21 °C) and lighting with 12h/12h
light/dark cycle. They received a standard mouse diet and
water ad libitum. Mice were randomized into four groups (8
mice/group): (1) a control group receiving daily intraperitone-
ally (i.p.) injections of PBS; (2) a group injected daily i.p. with
human PTH (1–34) alone (80μg/kg/day, dissolved in 1mM
HCl containing 0.2% bovine serum albumin); (3) a group
injected daily subcutaneously (s.c.) with L-NAME alone
(30mg/kg/day); and (4) a group co-administered daily with
PTH and L-NAME at the doses specified above. All groups
were treated for 28 days. The body weight of all mice was
measured every day.
To measure bone formation rates, mice were injected s.c.
with calcein (15mg/kg), xylenol orange (90mg/kg) and
calcein again, respectively before the beginning of treatments,
7 days and 2days before the end of the study.
Blood perfusion in one hind limb was monitored during
the administration of treatments (acute effect) by laser
Doppler imaging (LDI) under general anaesthesia. All mice
underwent one LDI measurement on the first day of dosing
and then each mouse was imaged on at least two further
occasions, throughout the duration of the study. The acute
effect of PTH on intraosseous cortical bone perfusion was
assessed by intravenous infusion of a bolus of a fluorescent
tracer in two additional groups of naïve mice (n=4),
injected either with human PTH (1–34) (80μg/kg) or PBS.
At the end of the study, mice were sacrificed by neck
dislocation, left femurs were dissected, fixed in 10% buffered
formalin for 48h and stored in 70% ethanol for micro-
computed tomography (microCT) imaging and undecalcified
histomorphometry. Right femurs were dissected and immedi-
ately frozen for subsequent mechanical tests.
All procedures were performed in accordance with the prin-
ciples and guidelines established by the Animals Scientific
Procedures Act and UK Home Office regulations (PPL:
70/7444).
Measurements of whole hind limb and intraosseous cortical
bone perfusion
Two days before hind limb perfusion measurements, the
inner side of the hind limb to be imaged was shaved with
a depilatory cream under general anaesthesia. At the time
of the measurement, mice were anesthetized with 2%
isoflurane. Body temperature was maintained between at
36 and 37 °C with a feedback-controlled heating pad
(507220F, Harvard Apparatus, UK). Hind limb perfusion
was measured using a laser Doppler imaging (LDI) flow
meter (MoorLDI2 Imager, Moor Instruments Ltd, UK).
The instrument measures the distribution of blood flux
(combination of velocity and concentration of red blood
cells) in arbitrary units for a selected region of interest
(19mm×27mm) with a special resolution of 100μm/pixel.
The estimated maximum depth of detectable vessels (in soft
connective tissue) was estimated to be 2–3mm (laser
wavelength=830nm).
For the perfusion measurements, reagents were adminis-
tered in the same order as during the chronic study: first
PBS or L-NAME was injected subcutaneously and then
PBS or PTH (1–34) was injected i.p. within 10min after
the first injection. Perfusion was recorded continuously for
30min (starting 10min before the first injection).
Vascular tracer uptake into the lacuno-canalicular porosity,
an established method to measure intraosseous perfusion 30,31,
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was assessed by injecting a bolus of procion red solution
(0.8% in PBS), equal to 10% of the body weight, into the tail
vein of naïve mice. The procion red bolus was given to two
groups of restrained, conscious mice (n=4) immediately after
i.p. injection of either PTH (1–34) or PBS. Mice were allowed
to roam freely in their cages for 5min after the injection, and
then sacrificed by neck dislocation. Femurs were immediately
dissected and fixed in 70% ethanol. Procion red uptake in
cortical bone was examined in non-decalcified histological
sections of the femoral mid-diaphysis using the protocol
described below.
Assessment of microstructure and volumetric bone mineral
density by microCT
The microstructure and volumetric bone mineral density
(vBMD) of femurs were assessed by high-resolution microCT
(5μm/pixel, 50kV, 200μA, Skyscan 1172, Belgium). Image
reconstruction was performed by NRecon software (Skyscan)
and bone parameters were analysed in 2D and 3D using CT.
An software (Skyscan). The cortical and trabecular compart-
ment within the femoral metaphysis and the vertebral body
were determined by manual contouring. Specifically, the
trabecular bone within the secondary spongiosa was analysed
in the femoral metaphysis, a volume extending 1mm proxi-
mally from the primary spongiosa limit (200 tomograms). In
the vertebral body, the entire trabecular content extending
between the two cortical plates was contoured and analysed.
The threshold values for the microCT analysis of trabecular
bone were chosen between 60 and 255, while they were
between 100 and 255 for cortical bone. The following stan-
dard histomorphometric parameters were evaluated in
trabecular bone using a 3D-based analysis software (Ct.
An, Skyscan): bone volume fraction (BV/TV, computed
as the ratio of bone volume, BV, over tissue volume, TV), tra-
becular thickness (Tb.Th), trabecular space (Tb.Sp), trabecular
number (Tb.N) and 3D structure model index (SMI), trabecular
pattern factor (Tb.Pf), trabecular connectivity density (Conn.D).
Cortical bone in the mid-diaphysis was evaluated in 50
tomograms located at 50% of the total length of femur.
The following parameters were evaluated in cortical bone
using Ct.An and Matlab software: tissue volume (TV), bone
volume (BV), average cross-sectional tissue area (Tt.Ar),
average cross-sectional bone area (Ct.Ar), average cross-
sectional cortical thickness (Ct.Th), maximum moment of
inertia (Imax), minimum moment of inertia (Imin), polar
moment of inertia (Ipol), volumetric bone mineral density
(vBMD) and percentage porosity.
Non-decalcified bone histomorphometry
After microCT scanning, femurs were dehydrated and
embedded in methyl methacrylate using an established cold
embedding protocol which preserves tartrate resistant acid
phosphatase (TRAP) enzymatic activity 32. Thicker cross
sections of the femur mid-diaphysis (70–100μm) were
obtained using a slow-speed rotating saw (Isomet, Buehler,
USA) while thinner coronal sections of the femur distal
metaphysis (8μm thick) were cut with a microtome
(RM2255, Leica, Germany). To determine the osteoclast
surface per bone surface (Oc.S/BS), sections were stained
for TRAP (Leucognost SP kit, Merck) and counterstained
with Weigert’s haematoxylin. To determine the osteoid
surface per bone surface (Ost.S/BS), sections were stained
using a modified Goldner’s trichrome protocol.
Fluorescent labels were visualized using a confocal laser
scanning microscope (TCS SP5, Leica, Germany) equipped
with 488nm (for calcein) and 561nm (for xynelol orange)
lasers. For cortical bone, double calcein-labels were measured
using an Osteometrics image analysis software system, and
the following parameters were evaluated: mineralizing
surfaces (MS/BS, %), computed as the last calcein labelled
surfaces (MS, μm2) normalized to all bone surfaces (BS,
μm2); mineral apposition rate (MAR, μm/day), measured as
average distance between adjacent pairs of calcein labels
divided by the number of days elapsed between the adminis-
tration of both labels (26days); bone formation rates (BFR/
BS, μm3/μm2/d), derived by multiplying MS/BS by MAR.
For trabecular bone, only mineral apposition rate was eval-
uated using a dedicated open source plugin for Image J
developed in our laboratory. We measured the distance
between the xynelol orange label and the last calcein label
(5 days between both labels). All histomorphometric
parameters were quantified using a semi-automated pro-
gramme, developed by Dr. van’t Hof 33.
Procion red uptake in the mid-shaft cortical bone was
assessed in the thick sections (70–100μm) by confocal mi-
croscopy (excitation laser =561nm, emission filter =610nm).
Briefly, a region of interest (ROI) was manually drawn within
the postero-medial quadrant of the mid-diaphysis cortical bone.
The average fluorescence intensity of each ROIwas normalized
by the area of the ROI and was used a measure of the average
concentration of the tracer per unit area of cortical bone.
Assessment of bone mechanical properties
For biomechanical analysis, right femurs were stored in
gauze soaked in saline solution at80 °C and thawed before
analysis at room temperature. They were tested until fracture
by three-point bending using an Instron testing machine
(5866, Norwood, MA, USA). Femurs were loaded at the
mid-diaphysis in their antero-posterior direction with a
deflection rate of 1μm/s while load was measured using a
calibrated 50-N load cell. The loading span (i.e. the distance
between the two rods supporting the femur shaft) was fixed
to 9mm. Femora were kept moist at all times. Force–deflection
curves were analysed with a custom programme in Matlab
(MathWorks Inc, MA, USA). Geometry parameters, including
the mid femur cross-section dimensions were measured from
the microCT images of the femur mid-diaphysis.
Bending stress (σ) was computed from the force according
to the equation: σ=FLd/4Imin, where F is the force, L is the
loading span, d is the antero-posterior diameter and Imin is
the second moment of inertia from the lateromedial axis
(πd^4⁄64); bending strain (e) was calculated according to the
equation: e=deflection×6×d / (L^2); 34. The following set
of parameters—regarded as extrinsic mechanical properties
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—was directly measured from the force–deflection curves:
bending stiffness (S, slope of the linear elastic deformation),
yield load (Fyield, force limit between the elastic and plastic de-
formation), ultimate load (Fult, maximum force sustained) and
breaking load (Fbreak, force at which the bone breaks). An
additional set of parameters—regarded as intrinsic mechanical
properties—was computed using the standard beam theory
from the stress–strain curves derived from the force–
deflection curves 34. These included: bone elastic modulus
(E, slope of the linear elastic deformation in the stress-
strain curve), yield stress (σyield, stress limit between the
elastic and plastic deformation), ultimate stress (σult,
maximum stress sustained) and breaking stress (σbreak,
stress at which the bone breaks). Finally, total and plastic
(yield) work to fracture, as well as their ratio, were calcu-
lated as a measure of bone toughness.
Statistical analysis
Data are reported as mean± standard deviation (SD). Results
were analysed by one-way ANOVA, followed by Dunnett’s
post hoc test. Tukey’s post hoc test was used to compare all
possible pairings in the four groups. The homoscedasticity
requirement (equal variances across groups) for the applicabil-
ity of one-way ANOVA was established by the Bartlett’s and
the Brown–Forsythe test (which was not significant for all sets
of parameters tested). Statistical analysis was computed using
Prism v.6 software (GraphPad, USA). A two-tailed P value
less than 0.05 was regarded as statistically significant.
RESULTS
iPTH induces acute but not chronic increases in both
intra-cortical and hind limb perfusion that are abolished by
L-NAME co-administration
The mean body weight of mice did not change during the 4-
week treatment, and was similar among the four treatment
groups (vehicle=25.3±0.4g, iPTH=25.5±0.5g, iPTH+L-
NAME=25.4±0.3g, L-NAME=25±0.8g, mean±SD,
n=10–14). Acute changes in hind limb perfusion were measur-
able by LDI on the first day of dosing, with PTH producing
significant elevation (over 30%; P< 0.001) in perfusion within
10–15min compared to the vehicle-treated controls, which was
sustained for ≥30min (Figure 1 a, b). Notably, this acute
response was reproduced in randomly selected mice after any
of the daily doses of PTH throughout the 4-week period (ap-
proximately two randommeasurements in each mouse, besides
the initial one). While L-NAME alone had little decreases
compared to the control, its co-administration completely
blocked the PTH-related increases in vasorelaxation (Figure 1
a, b). However, at the end of the 4-week treatment, no measur-
able chronic changes in hind limb blood perfusion were evident
24h after the last dosing in any groups compared to vehicle
controls (vehicle=641±112, PTH=775±215, iPTH+L-
NAME=734±117, L-NAME=678±122, perfusion expressed
in arbitrary units, mean±SD, n=10–14). These data indicate that
iPTH induces acute, but not chronic increases in hind limb
perfusionwhich are abolished by co-administration of L-NAME,
suggesting that they aremediated by increases in NO production.
This iPTH-induced hind limb perfusionmight not necessar-
ily be translated to changes in intra-cortical bone perfusion;
therefore, in order to relate whole hind limb perfusion (mea-
sured by LDI) to direct intracortical bone perfusion, we used
confocal microscopy to assess uptake of procion red in corti-
cal bone of the femoral mid-diaphysis. Our data revealed that
PTH significantly increases procion red average fluorescence
(proportional to its concentration) in femoral cortical bone
within 5min of injection (Figure 2 a, b). This suggests that
PTH injection induces both acute elevation in blood perfusion
and a closely linked increase in tracer perfusion within the
femoral cortical bone tissue.
iPTH induced increases in cortical bone volume and bone
formation rate that are partially blunted by L-NAME
co-administration
Cortical bone geometry and bone quality parameters in the
femoral mid-diaphysis were measured by microCT. As
expected, significantly increased cortical bone volume
(+12%) and average thickness (+10%) were observed in mice
treated with iPTH compared to vehicle-treated mice (Figure 3
a, b). Moreover, cortical tissue volume was slightly higher in
iPTH-treated mice compared with vehicle treated mice,
although this was not significant (P=0.059). These iPTH-
induced changes were abrogated by co-administered L-
NAME treatment, which effectively restrained cortical bone
geometry to levels evident in control mice. L-NAME treat-
ment alone had no effect (Figure 3 a, b). Additional measures
of mid-shaft geometry (Table 1) were also significantly ele-
vated by iPTH compared with control, including Imin
(+18%) and Ipol (+16%), and these were similarly reduced
to basal control levels by co-administration of L-NAME.
MicroCT analysis of bone quality indexes, including bone
mineral density (BMD) and cortical porosity, showed that
these were unchanged in the experimental groups (Table 1).
Because of the differences in blood supply between the
bone periosteal surfaces (normally well vascularized) and
the endosteal surfaces (poorly supplied) 35, we investigated
whether the modulation of vascular function induced by
the different treatments might produce differing levels of
osteoblastic activation in each of these two envelops. Quan-
tifying bone formation rate in the whole bone and separately
in periosteal and endosteal bone compartments revealed that
the whole bone response more closely matched the perios-
teal response (Figure 4 a–c). Intermittent PTH treatment
significantly increased mineral apposition rate (MAR) and
bone formation rate (BFR/BS) on the periosteal surfaces
compared to vehicle-treated controls (+92% and +130%,
respectively) (Figure 4 a–c). These iPTH-induced increases
in MAR and BFR/BS were significantly suppressed by
co-administration of L-NAME (by 40%). These levels
were nevertheless still significantly elevated when com-
pared to either vehicle (+39%) or L-NAME-treated groups
(+48%), despite the lack of any modification in MAR or
BFR/BS by L-NAME treatment alone (Figure 4 a–c).
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Figure 1. Intermittent PTH increases bone blood flow acutely in BALB/c mice. (a) Representative images of the mouse hind limb perfusion, obtained by laser
Doppler imaging (LDI). Images acquired 10min after administration of vehicle, PTH 1–34 (80μg/kg), L-NAME (30mg/kg) or the combination PTH+L-NAME.
The colours in the heat maps indicate the maximum (red) and the minimum (blue) level of perfusion expressed in arbitrary units representing the total blood flux
(combination of velocity and concentration of red blood cells). (b) Time course graph of the average hind limb perfusion monitored by LDI for PTH and L-NAME,
alone or in combination. Arrows: 1—Vehicle or L-NAME injection; 2—vehicle or PTH. Values are presented as means ± standard errors of the mean (S.E.M.);
n = 10–14 mice/group; *P< 0.05 versus Control; *** P< 0.001 versus Control
Figure 2. Acute effect of PTH treatment on lacunar–canalicular perfusion. (a) Representative confocal micrographs of non-decalcified sections of the femoral
mid-diaphysis showing the uptake of fluorescent tracer in cortical bone 5min after injection of vehicle (control) and PTH 1–34 (80 μg/kg). Scale bar = 100 μm.
(b) Average tracer fluorescence within a region of interest manually drawn within the postero-medial quadrant of the mid-diaphysis cortical bone. Values are
mean ± SD, n = 4 mice/group; * P< 0.05 versus Control
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Conversely, BFR/BS was elevated on the endosteal surfaces
in the iPTH (+120%) and L-NAME alone (+142%) groups
compared to control, but not in the iPTH+L-NAME group
(Figure 4e), where it was significantly reduced in comparison
with the iPTH group (66%; Figure 4e).
In summary, L-NAME co-administration either partially
or completed inhibited the increase in the rate of bone for-
mation induced by iPTH, and this inhibition was dependent
upon the cortical bone envelope (periosteal or endosteal) of
the femur midshaft.
Co-administration of L-NAME with PTH reduces trabecular
bone volume
We then analysed trabecular bone in the femoral metaphysis
in order to determine whether similar sensitivity to L-NAME
and iPTH was evident in this highly vascularized compart-
ment. In contrast to the anabolic effect of PTH in cortical
bone, microCT analysis of the femoral metaphysis showed
that iPTH treatment in BALB/c mice induced a decrease in
trabecular number (Tb.N; 21%) and augmented trabecular
thickness (+27%) without any modification in total trabecular
bone volume fraction (BV/TV; Figure 5 a–d). L-NAME treat-
ment alone did not significantly affect any trabecular bone
parameter, compared to controls (Figure 5 a–e) but its co-
administration with iPTH resulted in decreased BV/TV
(15%), greater reduction in Tb.N (32%) and further en-
hanced Tb.Th (+24%) compared to vehicle-treated controls
(Figure 5 a–d). iPTH also elevated the structural model index
(SMI; +20%), which was further increased by L-NAME co-
administration (Figure 5 e). Additional measures of tra-
becular bone parameters (Table 1) were also significantly
Figure 3. L-NAME decreases the anabolic action of intermittent PTH on cortical bone volume. (a) Three-dimensional (3D) renderings of 2-mm segments of
the femur mid-diaphysis imaged by microCT at the end of 28-day treatment with vehicle (control), iPTH and L-NAME, alone or in combination. (b) Structural
parameters computed from the microCT scans: mid-diaphysis cortical bone volume (Ct.BV) and cortical bone thickness (Ct.Th). Values are mean ± SD, n = 7–8
mice/group; * P< 0.05 versus Control; ** P< 0.01 versus Control
Table 1. MicroCT analysis of femoral mid-diaphysis cortical bone and distal metaphysis trabecular bone. Femora were dissected at the end of the 28-day
dosing and analysed by micro-CT. Bone parameters are shown for the four treatment groups (n = 7–8 mice/group): Vehicle (control), iPTH, iPTH + L-
NAME and L-NAME alone
Cortical bone parameters Control iPTH iPTH+L-NAME L-NAME
Tissue volume, TV (mm3) 0.028 ± 0.001 0.030 ± 0.001 0.028 ± 0.001 0.029 ± 0.001
Cross-sectional tissue area, Tt.Ar (mm2) 0.105 ± 0.009 0.112 ± 0.004 0.107 ± 0.004 0.107 ± 0.007
Cross-sectional bone area, Ct.Ar (mm2) 0.064 ± 0.005 0.072 ± 0.003a 0.068 ± 0.002 0.066 ± 0.005
Imax (mm4) 0.23 ± 0.04 0.27 ± 0.03 0.24 ± 0.02 0.24 ± 0.03
Imin (mm4) 0.10 ± 0.02 0.12 ± 0.01a 0.11 ± 0.01 0.11 ± 0.01
Ipol (mm4) 0.0016 ± 0.0003 0.0019 ± 0.0001a 0.0017 ± 0.0001 0.0017 ± 0.0002
vBMD (g/cm3) 1.269 ± 0.017 1.278 ± 0.010 1.276 ± 0.013 1.279 ± 0.010
Cortical porosity (%) 0.04 ± 0.02 0.04 ± 0.05 0.02 ± 0.03 0.05 ± 0.05
Trabecular bone parameters Control iPTH iPTH+L-NAME L-NAME
Trabecular space, Tb.Sp (mm) 0.18 ± 0.01b 0.21 ± 0.01abc 0.23 ± 0.01ac 0.19 ± 0.01b
Trabecular pattern factor, Tb.Pf (mm1) 20.9 ± 2.5b 21.3 ± 1.8b 24.5 ± 2.2a 22.7 ± 1.9
Connectivity density, Conn.D (mm-3) 290.4 ± 35.5b 183.4 ± 25.0abc 144.8 ± 18.6ac 273.7 ± 37.7b
Values are mean ± SD;
aP< 0.05 versus control;
bP< 0.05 versus iPTH + L-NAME;
cP< 0.05 versus L-NAME.
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modified by iPTH and by L-NAME. Tb.Sp was increased
by iPTH compared to control (+16%) and further increased
by L-NAME co-administration. iPTH co-administrated with
L-NAME increased Tb.Pf compared to controls (+17%) and
iPTH alone (+15%). Conn.Dn was reduced by PTH treatment
compared to control (37%), and greater reductions were
observed with L-NAME co-administration (50%; Table
1). Similar microstructural changes were observed in the
trabecular bone of L5 vertebrae (data not shown), indicating
a compartment-specific (trabecular versus cortical bone) but
not a site-specific (appendicular versus axial skeleton) sensi-
tivity to iPTH and L-NAME treatment.
In order to determine osteoblast and osteoclast activities, we
also examined histomorphometric parameters of trabecular
bone in the distal femur metaphysis. The percentage of resorp-
tion surfaces was not significantly different among groups
(Figure 6 a–c). The proportion of osteoid surfaces was signif-
icantly greater in both iPTH (+167%) and PTH+L-NAME
treated groups (+133%) than control (Figure 6 d–f). Although
L-NAME co-administration appeared to reduce the elevation
of osteoid surfaces compared to iPTH alone, this did not reach
statistical significance. L-NAME treatment alone did not
affect any of the cellular parameters. Despite the significant
increase in osteoid surfaces induced by iPTH, the bone appo-
sition rate (MAR) in trabecular bone was not affected by any
of the treatments (Figure 6 g–i). Thus, iPTH appear to regulate
bone remodelling by altering the thickness and number of tra-
beculae without inducing a final increase in trabecular bone
volume fraction compared to control. Co-administration of
L-NAME did not reduce iPTH-induced trabecular thickening
but did further decrease the number of trabeculae which resulted
in a final reduction of the trabecular bone volume fraction.
L-NAME co-administration does not modify iPTH-enhanced
bone mechanical strength
In order to explore whether these changes in perfusion and
associated modifications in bone formation and geometry
engender a structural advantage, we measured whole-bone
mechanical properties by three-point bending. This showed
that iPTH significantly increased several extrinsic bone
material properties compared to control (Table 2), including
yield load (+17%) and ultimate load (+15%), which measure
whole femur strength. Surprisingly, this iPTH-induced
enhancement in bone strength was not reduced by co-
administration of L-NAME. Moreover, iPTH and L-NAME
in combination exerted unexpected effects on some of the
intrinsic material properties of bone, including Young’s
modulus, yield stress and ultimate stress, which were signif-
icantly increased compared with bones from both control
and also with iPTH-treated groups (Table 2). Conversely,
iPTH did not affect any of the intrinsic material properties
Figure 4. L-NAME reduces iPTH-induced increases in cortical bone formation rate. (a) Representative confocal micrographs of non-decalcified sections of
the femoral mid-diaphysis, showing the calcein double labels (26 days between both labels) marking bone apposition during the 26 days of dosing with vehicle
(control), iPTH and L-NAME, alone or in combination. Scale bar = 50μm. (b) Bar graphs of the average periosteal mineral apposition rate (MAR) and (c) periosteal
bone formation rate (BFR/BS) for the four groups. (d) Bar graphs of the average endosteal mineral apposition rate (MAR) and (e) endosteal bone formation rate (BFR/
BS) for the four groups. Values are mean ± SD, n= 7–8mice/group; a P< 0.05 versus control; b P< 0.05 versus iPTH; c P< 0.05 versus iPTH+L-NAME, d P< 0.05
versus L-NAME
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of cortical bone compared to control. Finally, L-NAME
alone did not affect either extrinsic or intrinsic material
properties of bone compared with control. These data indi-
cate that the combined effect of opposing modifications in
structural versus material properties induced by iPTH versus
those in the presence of PTH+L-NAME caused the two
treatment groups to achieve a similar improvement in femur
mechanical strength compared with control.
DISCUSSION
The results of the present study show that PTH (1–34)
causes acute stimulation of limb blood flow in BALB/c
mice, and that this response is required for PTH to achieve
its anabolic effect on cortical bone. PTH treatment however
did not increase trabecular bone volume in BALB/c mice.
Our data also shows that the vasomotor effect of PTH is
not diminished by repeated daily dosing. This observation
suggests that the transient surge in blood perfusion follow-
ing daily PTH administration may be integral to the mode
of action of intermittent PTH on bone.
We demonstrate that blockade of nitric oxide synthase
activity by the inhibitor L-NAME greatly reduced PTH-
stimulated blood flow and also restricted the anabolic effect
of PTH on cortical bone. These results fit with the earlier
finding that PTH-induced acute vasodilation in rat femoral
principal nutrient arteries in vitro was almost totally
inhibited by L-NAME 26, and suggest a significant role for
NO-mediated arterial vasorelaxation in the osteoanabolic
actions of PTH. Bone cells also signal through NO 36,37,
and thus specific interactions between PTH and NOS in
bone cells cannot be ruled out, although in vitro evidence
suggests that NO production is not significantly altered by
PTH in human and murine osteoblasts 38,39. Our results
showed that L-NAME treatment alone did not significantly
affect perfusion or bone mass, suggesting that NOS function
may not play an important role in bone homeostasis in
unchallenged adult mice. This is consistent with another
report showing that L-NAME administration for 18 days
did not significantly change trabecular bone formation rate
in rats 40.
Because our laser Doppler imaging measurements only
incorporated perfusion near the surface of mouse hindlimbs
(to a maximum penetration depth in skin/muscle of about
2mm), we tested whether acute vasodilation also induced
an increase in intraosseous cortical perfusion. The reference
method to measure bone blood flow is the intravascular
injection of labelled microspheres41. However, a lot of studies
demonstrated a positive correlation between the standardized
measure of blood flow with labelled microspheres and blood
perfusion measured by the Laser Doppler Imaging42,
Figure 5. Effects of PTH and L-NAME on trabecular bone architecture in femurs. (a) Three-dimensional (3D) rendering of microCT scans of trabecular bone
in secondary spongiosa of the distal femur in mice treated with vehicle (control), iPTH and L-NAME, alone or in combination for 28 days. The bar graphs show
some of the parameters obtained from the 3D analysis of the trabecular architecture, including (b) the bone volume fraction (BV/TV), (c) the number of trabeculae
(Tb.N), (d) the trabecular thickness (Tb.Th) and (e) the structure model index (SMI). Values aremean ± SD, n = 7–8mice/group; a P< 0.05 versus control; bP< 0.05
versus iPTH; c P< 0.05 versus iPTH+L-NAME, d P< 0.05 versus L-NAME
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Figure 6. Effects of PTH and L-NAME on trabecular bone turnover. (a) Representative brightfield micrographs of non-decalcified sections of secondary spongiosa in
the distal femur stained for TRAP (a) or Goldner’s trichrome (d) with respective magnified regions demonstrating (b) TRAP-positive osteoclasts (arrow) or (e) positively
stained osteoid (arrow) lining trabeculae (Tb). (g) Representative confocal micrographs of a non-decalcified section of the secondary spongiosa of the distal
femur, showing the fluorescent labels (calcein, green and xylenol orange, red, 5 days between both labels) marking bone apposition during the last 5 days of
the 28 day dosing experiment. Scale: bars = 500 μm in top row images and bars = 50 μm in second row images. Bar graphs (C, F, I) summarize the different
histomorphometric parameters in trabecular bone at the end of the 28-day treatment with vehicle (control), PTH 1–34 (80μg/kg/d) and L-NAME (30mg/kg/d), alone or in
combination including: (c) percentage of osteoclast surface per bone surface, (f) percentage of osteoid surface per bone surface and (i) mineral apposition rate (MAR).
Values are mean ±SD, n= 7–8 mice/group; a P< 0.05 versus control; b P< 0.05 versus iPTH; c P< 0.05 versus iPTH+L-NAME, d P< 0.05 versus L-NAME
Table 2. Mechanical properties of the femurmeasured by the three-point bending test. Bone mechanical properties were measured in femurs dissected at the end of
the 28-day dosing for the four treatment groups (n = 7-8 mice/group): Vehicle (control), iPTH, iPTH+L-NAME and L-NAME alone
Group Control iPTH iPTH+L-NAME L-NAME
Diameter femurs (mm) 1.16 ± 0.06 1.22 ± 0.04 1.18 ± 0.03 1.19 ± 0.05
Yield load (N) 12.0 ± 1.3b 14.1 ± 1.0a 14.6 ± 1.5ac 12.5 ± 1.3b
Ultimate load (N) 13.5 ± 1.0b 15.5 ± 0.7a 16.6 ± 1.1ac 14.9 ± 1.7b
Breaking load (N) 10 ± 2 12 ± 2 11 ± 2 10 ± 4
Yield extension (mm) 0.18 ± 0.02 0.19 ± 0.03 0.18 ± 0.01 0.17 ± 0.03
Ultimate extension (mm) 0.26 ± 0.05 0.25 ± 0.03 0.24 ± 0.03 0.24 ± 0.05
Breaking extension (mm) 0.5 ± 0.1 0.4 ± 0.2 0.5 ± 0.1 0.4 ± 0.1
Stiffness (N/mm) 70 ± 6 80 ± 7 87 ± 10a 79 ± 11
Elastic modulus (MPa) 4763 ± 945 4530 ± 654b 5580 ± 516 5037 ± 363
Yield stress (MPa) 69 ± 9b 72 ± 6 83 ± 10ac 71 ± 8b
Ultimate stress (MPa) 78 ± 10b 79 ± 5b 93 ± 6a 84 ± 8
Breaking stress (MPa) 58 ± 9 61 ± 13 60 ± 7 57 ± 22
Yield strain 0.015 ± 0.002 0.017 ± 0.003 0.016 ± 0.001 0.015 ± 0.002
Ultimate strain 0.022 ± 0.005 0.023 ± 0.002 0.021 ± 0.003 0.021 ± 0.003
Breaking strain 0.04 ± 0.01 0.04 ± 0.02 0.04 ± 0.01 0.04 ± 0.01
Work to fracture (mJ) 4.3 ± 1.3 4.3 ± 2.2 5.1 ± 0.7 4.0 ± 1.7
Work yield to fracture (mJ) 3.3 ± 1.3 3.0 ± 2.2 3.8 ± 0.7 3.0 ± 1.7
Values are mean ± SD;
aP< 0.05 versus control;
bP< 0.05 versus iPTH + L-NAME;
cP< 0.05 versus L-NAME.
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demonstrating that the whole hindlimb blood flow is a good in-
dicator of bone blood flow.We found that daily PTH treatment
increased cortical bone perfusion (assessed by procion red
staining), consistent with previous studies reporting a PTH-
induced elevation of radioactive microspheres uptake in the
tibiae of rats 43. Our results are also consistent with the recent
findings of Roche et al. 22, who showed that tibial perfusion
and blood vessel area increased in response to daily PTH injec-
tion. In contrast, though, we did not observe any chronic
changes in mouse hind limb perfusion, measured by laser
Doppler, following prolonged daily administration of
PTH. However, because of technical limitations, we were
not able to measure cortical perfusion at the end of our
study, and thus cannot exclude the possibility that iPTH
might have a chronic effect on this parameter.
Our finding that the anabolic effect of iPTH on cortical
bone was not completely blocked by L-NAME suggests that
other bone and/or vascular responses are triggered by the
activation of PTHR1 receptor independently of NOS activ-
ity. One possibility is the involvement of VEGF signalling,
because a VEGF-blocking antibody has been reported to
abolish the anabolic effect of PTH and impair bone blood
vessel remodelling in vivo 23, as well as reducing vasodila-
tion in vitro 26. Alternatively, and irrespectively of the
changes in perfusion, PTH may act on osteocytes to
decrease production of the Wnt signalling and bone forma-
tion inhibitor, sclerostin 7. Our observation that L-NAME
inhibition of the osteoanabolic effect (MAR and BFR/BS)
of iPTH on cortical bone was more prominent on endosteal
surfaces fits the view that the vascular effect of PTH is
particularly marked in more hypoxic areas of bone such as
the endosteum and less essential at more oxygen-replete
periosteal surfaces 35. This differential stimulation of bone
formation in response to the different treatments on cortical
bone external and internal envelops suggests a complex
remodelling of the mineral surfaces of these envelops, which
may contribute to changes in the material properties and,
ultimately, the mechanical strength of bone.
Notwithstanding its inhibition of PTH-induced cortical
osteogenesis, L-NAME co-administration did not affect the
mechanical strength of the femurs. The reasons for this are
not completely clear but it could be that the reduction in
PTH-induced cortical osteogenesis by L-NAME was com-
pensated by other changes in the intrinsic mechanical prop-
erties of the bones in order to achieve the same overall
mechanical strength 44. Indeed, we observed that L-NAME
treatment improved the intrinsic mechanical properties of
the cortical bone compared to control, while PTH alone
had no effect. However, we were unable to detect any changes
in either BMD or cortical porosity by microCT in PTH and L-
NAME-treated groups. Alternatively, it is possible that any
changes in mechanical strength are below the powers of detec-
tion of this methodology.
We did not observe any effect of iPTH on the trabecular bone
volume fraction (BV/TV) in the distal femoral metaphysis. We
noted a similar lack of effect of iPTH in the trabecular bone of
the L5 vertebra (data not shown), suggesting that this was not a
site-specific phenomenon. This lack of effect was surprising,
given that several reports have documented a strong increase
in trabecular bone mass in C57Bl/6 mice administered similar
doses of iPTH for 15 to 28days 22,45,46. It was however shown
that the responsiveness to anabolic actions of PTH is mouse
strains dependent, 47 and it is likely that our results may reflect
responses that are specific for the BALB/cmouse strain, consis-
tent with a previous report 48. It is also possible that our lack of
effect of iPTH on trabecular BV/TV may be related to the age
of the animals studied, because iPTH has been shown to
increase metaphyseal trabecular bone in younger BALB/c
mice 49. The lack of BV/TV elevation by iPTH in our study
did not appear to reflect the complete absence of an effect but
rather an homeostatic response where the increase in trabecular
thickness (Tb.Th) was compensated by a decrease in the number
of trabeculae (Tb.N). Moreover, the proportion of trabecular
surfaces covered by osteoid was increased by iPTH and
unaffected by co-treatment with L-NAME, suggesting that iPTH
augmented trabecular bone matrix formation independently of
NOS activity. This increase was not matched, however, by an
accrual in mineralized bone matrix. Additionally, the reduc-
tion in Tb.N in the iPTH treated mice does not fit with the lack
of change in osteoclast surfaces. The reasons for the lack of
concordance of histomorphometric and microCT parameters
in trabecular bone are unclear.
In conclusion, by demonstrating that the acute vasorelax-
ation induced by PTH modulates its anabolic effect on
cortical bone in BALB/c mice, the current study provides
new evidence for a novel mode of action for iPTH in bone,
through an indirect, transient vasomotor stimulation which
intermittently increases bone perfusion. Our simplest
explanation of this action is that the daily boost of oxygen
and nutrients induced by iPTH in bone might be responsible
for accelerating bone cell metabolism and, ultimately,
increasing bone formation. In addition, changes in intraosseous
perfusion are bound to alter gradients for hypoxia in the bone
marrow with the potential of activating quiescent osteoblasts
and/or mobilizing osteogenic progenitor cells 50. Our results
support the notion that daily pharmacological stimulation of
vasodilation could either boost the effect of osteoanabolic drugs
or by itself increase bone formation and bone mass.
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